Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Act now to curb Omicron's spread, WHO's Tedros tells world

Published 08/12/2021, 16:30
Updated 08/12/2021, 18:15
© Reuters. FILE PHOTO: World Health Organization chief Tedros Adhanom Ghebreyesus attends a ceremony to launch a multiyear partnership with Qatar on making FIFA Football World Cup 2022 and mega sporting events healthy and safe at the WHO headquarters, in Geneva, Swi

© Reuters. FILE PHOTO: World Health Organization chief Tedros Adhanom Ghebreyesus attends a ceremony to launch a multiyear partnership with Qatar on making FIFA Football World Cup 2022 and mega sporting events healthy and safe at the WHO headquarters, in Geneva, Swi

By Stephanie Nebehay

GENEVA (Reuters) -Governments need to reassess national responses to COVID-19 and speed up vaccination programmes to tackle Omicron, though it is it too early to say how well existing shots will protect against the new variant, the World Health Organization said on Wednesday.

The variant's global spread suggests it could have a major impact on the COVID-19 pandemic, and the time to contain it is now before more Omicron patients are hospitalised, WHO director-general Tedros Adhanom Ghebreyesus said.

"We call on all countries to increase surveillance, testing and sequencing," he told a media briefing. "... Any complacency now will cost lives."

WHO emergency director Mike Ryan said that as the variant appears to be more easily spread, efforts must be redoubled to break chains of transmission.

The WHO noted early evidence from BioNTech and Pfizer (NYSE:PFE) of the effectiveness of their vaccine against Omicron.

The German and U.S. companies said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test, while two doses resulted in lower neutralising antibodies by a factor of 25.

Warning against jumping to conclusions from the test, the WHO's chief scientist said it was too soon to say whether the reduction in neutralising antibodies meant the shot was less effective.

"It is premature to conclude that this reduction in neutralising activity would result in a significant reduction in vaccine effectiveness. We do not know that because as you know the immune system is much more complex," Swaminathan said.

"And so what we need now is a coordinated research effort and not jumping to conclusions study by study."

Ana Maria Henao-Restrepo, WHO head of research and development unit, said that its closed-door meeting of experts on Monday had reviewed variability in the results of early data on vaccine effectiveness against Omicron.

"Neutralising antibodies are an important piece of information, they play an important role in the control of the infection, but they are only one part of the protection against severe disease," she said.

© Reuters. FILE PHOTO: World Health Organization chief Tedros Adhanom Ghebreyesus attends a ceremony to launch a multiyear partnership with Qatar on making FIFA Football World Cup 2022 and mega sporting events healthy and safe at the WHO headquarters, in Geneva, Switzerland, October 18, 2021. Fabrice Coffrini/ Pool via REUTERS

The WHO also said it would publish a review of its stance on booster doses within days, but with vaccination rates worryingly low in much of the developing world, administering primary doses - rather than boosters - remained its priority.

"Wholesale boosters are not the solution," Swaminathan said.

Latest comments

this lot have no credibility whatsoever
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.